Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Pharmaceuticals Inc.

www.regeneron.com

Latest From Regeneron Pharmaceuticals Inc.

AbbVie’s Post-Humira Strategy Continues Taking Shape With Rinvoq Approval

AbbVie now has both of its Humira successors approved in the US, following April’s Skyrizi approval for psoriasis. But Rinvoq faces stiff competition both within the JAK1 class and in rheumatoid arthritis generally.

Approvals Business Strategies

Regeneron’s Cholesterol Drug Aces Phase III, Teeing Up US FIling

The trial linked ANGPTL3 antibody evinacumab to a steep decline in LDL cholesterol in patients with homozygous familial hypercholesterolemia, setting Regeneron up to file for US FDA approval next year.

Clinical Trials Companies

Ebola Success For Regeneron’s Triple Antibody Cocktail

PALM study stopped early after two agents being tested proved better than ZMapp, the current standard of care, in the ongoing Ebola outbreak in the Democratic Republic of Congo. One is being developed by Regeneron.

Clinical Trials Companies

Inovio Eyes Expanded Asian Opportunities, Presence Via Korea Dual Listing

Inovio is poised to become the first US-listed company to dual-list in South Korea, as CEO tells Scrip it is seeking to increase its presence and find new opportunities in Asia, while benefiting from strong investor interest in the country’s "very exciting" and vibrant biotech industry.

South Korea Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Regeneron Pharmaceuticals Inc.
  • Senior Management
  • Leonard S Schleifer, MD, PhD, Pres. & CEO
    Robert E Landry, SVP, Fin. & CFO
    George D Yancopoulos, MD, PhD, Pres. & CSO
  • Contact Info
  • Regeneron Pharmaceuticals Inc.
    Phone: (914) 847-7000
    777 Old Saw Mill River Rd.
    Tarrytown, NY 10591
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register